Omentin attenuates atherosclerotic lesion formation in apolipoprotein E-deficient mice. 2016

Mizuho Hiramatsu-Ito, and Rei Shibata, and Koji Ohashi, and Yusuke Uemura, and Noriyoshi Kanemura, and Takahiro Kambara, and Takashi Enomoto, and Daisuke Yuasa, and Kazuhiro Matsuo, and Masanori Ito, and Satoko Hayakawa, and Hayato Ogawa, and Naoya Otaka, and Shinji Kihara, and Toyoaki Murohara, and Noriyuki Ouchi
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

OBJECTIVE Obesity is associated with the development of atherosclerosis. We previously demonstrated that omentin is a circulating adipokine that is downregulated in association with atherosclerotic diseases. Here, we examined the impact of omentin on the development of atherosclerosis with gain-of-function genetic manipulations and dissected its potential mechanism. RESULTS Apolipoprotein E-deficient (apoE-KO) mice were crossed with transgenic mice expressing the human omentin gene (OMT-Tg) mice in fat tissue to generate apoE-KO/OMT-Tg mice. ApoE-KO/OMT-Tg mice exhibited a significant reduction of the atherosclerotic areas in aortic sinus, compared with apoE-KO mice despite similar lipid levels. ApoE-KO/OMT-Tg mice also displayed significant decreases in macrophage accumulation and mRNA expression of proinflammatory mediators including tumour necrosis factor-α, interleukin-6, and monocyte chemotactic protein-1 in aorta when compared with apoE-KO mice. Treatment of human monocyte-derived macrophages with a physiological concentration of human omentin protein led to reduction of lipid droplets and cholesteryl ester content. Treatment with human omentin protein also reduced lipopolysaccharide-induced expression of proinflammatory genes in human macrophages. Treatment of human macrophages with omentin promoted the phosphorylation of Akt. Inhibition of Akt signalling abolished the anti-inflammatory actions of omentin in macrophages. CONCLUSIONS These data document for the first time that omentin reduces the development of atherosclerosis by reducing inflammatory response of macrophages through the Akt-dependent mechanisms.

UI MeSH Term Description Entries
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon

Related Publications

Mizuho Hiramatsu-Ito, and Rei Shibata, and Koji Ohashi, and Yusuke Uemura, and Noriyoshi Kanemura, and Takahiro Kambara, and Takashi Enomoto, and Daisuke Yuasa, and Kazuhiro Matsuo, and Masanori Ito, and Satoko Hayakawa, and Hayato Ogawa, and Naoya Otaka, and Shinji Kihara, and Toyoaki Murohara, and Noriyuki Ouchi
June 2009, European journal of nutrition,
Mizuho Hiramatsu-Ito, and Rei Shibata, and Koji Ohashi, and Yusuke Uemura, and Noriyoshi Kanemura, and Takahiro Kambara, and Takashi Enomoto, and Daisuke Yuasa, and Kazuhiro Matsuo, and Masanori Ito, and Satoko Hayakawa, and Hayato Ogawa, and Naoya Otaka, and Shinji Kihara, and Toyoaki Murohara, and Noriyuki Ouchi
April 2015, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,
Mizuho Hiramatsu-Ito, and Rei Shibata, and Koji Ohashi, and Yusuke Uemura, and Noriyoshi Kanemura, and Takahiro Kambara, and Takashi Enomoto, and Daisuke Yuasa, and Kazuhiro Matsuo, and Masanori Ito, and Satoko Hayakawa, and Hayato Ogawa, and Naoya Otaka, and Shinji Kihara, and Toyoaki Murohara, and Noriyuki Ouchi
January 2000, Advances in experimental medicine and biology,
Mizuho Hiramatsu-Ito, and Rei Shibata, and Koji Ohashi, and Yusuke Uemura, and Noriyoshi Kanemura, and Takahiro Kambara, and Takashi Enomoto, and Daisuke Yuasa, and Kazuhiro Matsuo, and Masanori Ito, and Satoko Hayakawa, and Hayato Ogawa, and Naoya Otaka, and Shinji Kihara, and Toyoaki Murohara, and Noriyuki Ouchi
September 1996, Proceedings of the National Academy of Sciences of the United States of America,
Mizuho Hiramatsu-Ito, and Rei Shibata, and Koji Ohashi, and Yusuke Uemura, and Noriyoshi Kanemura, and Takahiro Kambara, and Takashi Enomoto, and Daisuke Yuasa, and Kazuhiro Matsuo, and Masanori Ito, and Satoko Hayakawa, and Hayato Ogawa, and Naoya Otaka, and Shinji Kihara, and Toyoaki Murohara, and Noriyuki Ouchi
December 2023, Biochemical and biophysical research communications,
Mizuho Hiramatsu-Ito, and Rei Shibata, and Koji Ohashi, and Yusuke Uemura, and Noriyoshi Kanemura, and Takahiro Kambara, and Takashi Enomoto, and Daisuke Yuasa, and Kazuhiro Matsuo, and Masanori Ito, and Satoko Hayakawa, and Hayato Ogawa, and Naoya Otaka, and Shinji Kihara, and Toyoaki Murohara, and Noriyuki Ouchi
April 2015, Marine drugs,
Mizuho Hiramatsu-Ito, and Rei Shibata, and Koji Ohashi, and Yusuke Uemura, and Noriyoshi Kanemura, and Takahiro Kambara, and Takashi Enomoto, and Daisuke Yuasa, and Kazuhiro Matsuo, and Masanori Ito, and Satoko Hayakawa, and Hayato Ogawa, and Naoya Otaka, and Shinji Kihara, and Toyoaki Murohara, and Noriyuki Ouchi
January 2017, Frontiers in pharmacology,
Mizuho Hiramatsu-Ito, and Rei Shibata, and Koji Ohashi, and Yusuke Uemura, and Noriyoshi Kanemura, and Takahiro Kambara, and Takashi Enomoto, and Daisuke Yuasa, and Kazuhiro Matsuo, and Masanori Ito, and Satoko Hayakawa, and Hayato Ogawa, and Naoya Otaka, and Shinji Kihara, and Toyoaki Murohara, and Noriyuki Ouchi
September 2007, Endocrinology,
Mizuho Hiramatsu-Ito, and Rei Shibata, and Koji Ohashi, and Yusuke Uemura, and Noriyoshi Kanemura, and Takahiro Kambara, and Takashi Enomoto, and Daisuke Yuasa, and Kazuhiro Matsuo, and Masanori Ito, and Satoko Hayakawa, and Hayato Ogawa, and Naoya Otaka, and Shinji Kihara, and Toyoaki Murohara, and Noriyuki Ouchi
February 2003, Circulation,
Mizuho Hiramatsu-Ito, and Rei Shibata, and Koji Ohashi, and Yusuke Uemura, and Noriyoshi Kanemura, and Takahiro Kambara, and Takashi Enomoto, and Daisuke Yuasa, and Kazuhiro Matsuo, and Masanori Ito, and Satoko Hayakawa, and Hayato Ogawa, and Naoya Otaka, and Shinji Kihara, and Toyoaki Murohara, and Noriyuki Ouchi
October 2008, The Journal of nutritional biochemistry,
Copied contents to your clipboard!